Loading...
•
Dec 31, 2024
TELA Bio Q4 2024 Earnings Report
TELA Bio reported its Q4 2024 financial results with modest revenue growth and reduced operating expenses.
Key Takeaways
TELA Bio delivered a 4% increase in Q4 2024 revenue, supported by higher unit sales, despite facing pressure from lower average selling prices. The company reduced its operating expenses significantly, leading to a narrower net loss compared to the prior year.
Q4 2024 revenue reached $17,649,000, up 4% year-over-year.
Gross profit for the quarter was $11,221,000 with a 64% gross margin.
Net loss improved to $9,208,000 from $12,890,000 in Q4 2023.
Operating expenses decreased to $19,575,000, reflecting cost-efficiency efforts.
TELA Bio
TELA Bio
Forward Guidance
TELA Bio expects continued revenue growth and stable operating expenses in 2025, focusing on product adoption and market share expansion.
Positive Outlook
- Full-year 2025 revenue expected between $85 million and $88 million.
- Launch of OviTex IHR driving adoption in minimally invasive hernia procedures.
- Continued growth in unit sales volume across product lines.
- Cost-reduction efforts expected to maintain flat OpEx in 2025.
- Increased international sales contributing to growth opportunities.
Challenges Ahead
- Lower average selling prices due to product mix changes.
- Inventory adjustments affecting gross margin.
- Q4 revenue shortfall against internal expectations.
- Market competition and pricing pressures remain a challenge.
- Dependence on procedural volumes and hospital operations stability.